NASDAQ:MESO - Mesoblast Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.63 +0.20 (+3.11 %)
(As of 09/21/2018 03:32 AM ET)
Previous Close$6.4296
Today's Range$6.49 - $6.75
52-Week Range$4.74 - $7.79
Volume93,873 shs
Average Volume44,020 shs
Market Capitalization$578.89 million
P/E Ratio-10.52
Dividend YieldN/A
Beta2.03
Mesoblast logoMesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MESO
CUSIPN/A
Phone61-3-9639-6036

Debt

Debt-to-Equity Ratio0.11
Current Ratio4.21
Quick Ratio4.21

Price-To-Earnings

Trailing P/E Ratio-10.52
Forward P/E Ratio-6.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.34 million
Price / Sales36.01
Cash FlowN/A
Price / CashN/A
Book Value$5.80 per share
Price / Book1.14

Profitability

EPS (Most Recent Fiscal Year)($0.63)
Net Income$-35,290,000.00
Net Margins-203.51%
Return on Equity-10.48%
Return on Assets-8.66%

Miscellaneous

Employees81
Outstanding Shares94,170,000
Market Cap$578.89 million

Mesoblast (NASDAQ:MESO) Frequently Asked Questions

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

How were Mesoblast's earnings last quarter?

Mesoblast limited (NASDAQ:MESO) announced its quarterly earnings results on Wednesday, August, 29th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $2.51 million. Mesoblast had a negative return on equity of 10.48% and a negative net margin of 203.51%. View Mesoblast's Earnings History.

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release their next quarterly earnings announcement on Tuesday, November, 13th 2018. View Earnings Estimates for Mesoblast.

What price target have analysts set for MESO?

5 brokers have issued 12 month price objectives for Mesoblast's stock. Their forecasts range from $6.00 to $23.00. On average, they expect Mesoblast's share price to reach $15.60 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price. View Analyst Price Targets for Mesoblast.

What is the consensus analysts' recommendation for Mesoblast?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mesoblast.

What are Wall Street analysts saying about Mesoblast stock?

Here are some recent quotes from research analysts about Mesoblast stock:
  • 1. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (9/19/2018)
  • 2. Maxim Group analysts commented, "Mesoblast announced that the company entered into a partnership in (600535.SS – in chronic heart failure (CHF) and MPC-25-IC in acute myocardial infarction (AMI). We are factoring the China market into our model for HF and raising our price target to $16, from $14." (7/18/2018)
  • 3. Cantor Fitzgerald analysts commented, "We rate Mesoblast Overweight. We believe the company’s platform of mesenchymal lineage cell (MLC) therapies has the potential to treat an array of diseases with currently significant unmet needs. Valuation Summary We arrive at our 12-month price target of $23/share by assessing the after-tax, risk-adjusted NPV of future cash flows from Mesoblast’s MLC platform. The probability-adjusted, fully taxed NPV (15% discount rate) of future cash flows through 2030 is $2.3 billion (~$23 per ADR), in our calculation." (6/21/2018)

Who are some of Mesoblast's key competitors?

Who are Mesoblast's key executives?

Mesoblast's management team includes the folowing people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 61)
  • Dr. Donna L. Skerrett, Chief Medical Officer (Age 61)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 41)
  • Dr. Kenneth M. Borow M.D., Exec. (Age 70)

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Has Mesoblast been receiving favorable news coverage?

News coverage about MESO stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mesoblast earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned news stories about the company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Mesoblast.

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.05%).

Which major investors are selling Mesoblast stock?

MESO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $6.63.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $578.89 million and generates $17.34 million in revenue each year. The company earns $-35,290,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Mesoblast employs 81 workers across the globe.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]


MarketBeat Community Rating for Mesoblast (NASDAQ MESO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MESO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MESO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel